Australis Capital Past Earnings Performance
Past criteria checks 0/6
Australis Capital's earnings have been declining at an average annual rate of -53.2%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 93.2% per year.
Key information
-53.2%
Earnings growth rate
-34.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 93.2% |
| Return on equity | -112.9% |
| Net Margin | -528.7% |
| Last Earnings Update | 31 Mar 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Australis Capital makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 9 | -50 | 24 | 0 |
| 31 Dec 21 | 7 | -15 | 19 | 0 |
| 30 Sep 21 | 5 | -30 | 18 | 0 |
| 30 Jun 21 | 2 | -31 | 15 | 0 |
| 31 Mar 21 | 1 | -25 | 13 | 0 |
| 31 Dec 20 | 0 | -39 | 13 | 0 |
| 30 Sep 20 | 0 | -26 | 11 | 0 |
| 30 Jun 20 | 0 | -25 | 13 | 0 |
| 31 Mar 20 | 0 | -23 | 14 | 0 |
| 31 Dec 19 | 0 | -11 | 12 | 0 |
| 30 Sep 19 | 0 | -7 | 11 | 0 |
| 30 Jun 19 | 0 | -4 | 7 | 0 |
| 31 Mar 19 | 0 | -4 | 4 | 0 |
| 31 Dec 18 | 0 | -6 | 2 | 0 |
| 30 Sep 18 | 0 | -5 | 0 | 0 |
| 30 Jun 18 | 0 | -2 | 0 | 0 |
| 31 Mar 18 | 0 | 0 | 0 | 0 |
Quality Earnings: AUSA is currently unprofitable.
Growing Profit Margin: AUSA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AUSA is unprofitable, and losses have increased over the past 5 years at a rate of 53.2% per year.
Accelerating Growth: Unable to compare AUSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AUSA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Return on Equity
High ROE: AUSA has a negative Return on Equity (-112.89%), as it is currently unprofitable.